Background. In most seasons, the influenza vaccine is effective in preventing influenza, but it is not clear whether it is equally effective in preventing mild and severe cases. We designed a case-control study to compare the effectiveness of the influenza vaccine in preventing outpatient, inpatient, and severe or fatal cases of laboratory-confirmed influenza.
Influenza affects a significant percentage of the population annually and is associated with excess hospitalizations and mortality [1, 2] . In some people, influenza evolves to serious forms or worsens preexisting chronic conditions and requires hospitalization [3] .
Vaccination is the main influenza prevention strategy. In most seasons, influenza vaccination is effective in preventing outpatient cases of laboratory-confirmed influenza [4] [5] [6] [7] [8] [9] [10] [11] , influenza-associated hospitalizations [12] [13] [14] [15] [16] [17] [18] , and medically attended influenza in general [19] [20] [21] [22] [23] . However, there is little information on the differences in vaccine effectiveness between mild and severe cases.
Studies of influenza vaccine effectiveness in preventing all-cause deaths have generally obtained higher estimates than expected given the observed effectiveness against confirmed influenza cases [24] . For this reason, and also due to possible biases, these findings have raised some suspicion [25, 26] , which makes new studies evaluating the effect of influenza vaccination in preventing serious cases and deaths due to laboratoryconfirmed influenza necessary. Severe cases and deaths may be avoided by preventing influenza or by the contribution of vaccination in reducing complications or the worsening of the illness in people with influenza. However, it is not clear whether people in whom vaccination fails to prevent influenza have a different prognosis than nonvaccinated people with influenza.
The aim of this study was to assess and compare the effect of influenza vaccination in preventing outpatient visits, hospitalizations, and severe or fatal cases of laboratory-confirmed influenza. We also analyzed whether vaccination affects the severity of influenza cases.
METHODS

Study Population and Design
We carried out a matched case-control study with density sampling in 29 hospitals and their respective primary healthcare centers from 7 Spanish regions (Andalusia, the Basque Country, Castile and Leon, Catalonia, Madrid, Navarre, and Valencia Community) in the 2010-2011 season.
In Spain, the trivalent inactivated influenza vaccine was recommended and offered free of charge to people aged ≥65 years (≥60 in some regions) and to those with major chronic conditions. Other people can also be vaccinated if they pay for the vaccine. In all participant hospitals, patients admitted with influenza-like illness or acute respiratory disease were routinely swabbed for diagnosis. In the province where these hospitals are located, sentinel primary healthcare general practitioners take swabs from a systematically selected sample of outpatients with influenza-like illness according to the European case definition [27] . Swabbing criteria do not take into account the severity of patients or the vaccination status.
Patient Recruitment
Inpatient cases were patients admitted >24 hours to participating hospitals between October 2010 and April 2011 with influenzalike illness or acute respiratory infection, with influenza infection confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) in nasopharyngeal flocked swabs or nasopharyngeal wash collection. We excluded children aged <6 months, patients receiving antiviral treatment prior to hospitalization, and patients who had nosocomial infection, defined as influenza appearing ≥48 hours after admission for another cause.
We selected 4 matched subjects for each inpatient case. Two were outpatients attending primary healthcare centers: 1 who sought consultation for influenza that was confirmed by RT-PCR (outpatient case) and 1 who consulted for any reason other than influenza-like illness or acute respiratory infection (outpatient control). In addition, we selected 2 patients with unplanned hospital admission for reasons other than acute respiratory infection, influenza-like illness, septic shock, or multiple organ failure (inpatient controls). Inpatient controls and outpatient cases and controls were matched with each inpatient case according to age (±3 years in people aged <18 years and ±5 years in people aged ≥18 years), date of hospitalization or visit (±10 days), and the province of residence. Of the potentially eligible persons, we chose those who were closest in terms of the date of hospitalization and consultation. Occasionally, we recruited >1 patient who met the matching criteria for the same inpatient case and these were included in the analyses.
In inpatient cases, severe cases were defined as patients admitted to the intensive care unit (ICU) or who died in the hospital.
The study was approved by the ethics committees of the hospitals involved. Written informed consent was obtained from all patients included in the study.
Data Collection
Specifically trained health professionals used a structured questionnaire to collect information on cases and controls by interview and review of medical records. This information included sociodemographic variables, current smoking, pregnancy, major chronic conditions, unplanned hospitalization in the previous 12 months, bed confinement in the 7 days before hospitalization or medical visit, and other preexisting risk factors for complicated influenza. The following major chronic conditions that are an indication for influenza vaccination were recorded: chronic respiratory disease, asthma, cardiovascular disease, chronic renal disease, diabetes mellitus, immunodeficiency, neurologic disease or disability, neoplasia, chronic liver disease, rheumatologic disease, and body mass index ≥40 kg/m 2 . Other factors related to influenza complications were: pneumonia in the previous 2 years and systemic or inhaled corticoids.
Information on vaccination status, including the 2010-2011 seasonal trivalent influenza vaccine, monovalent influenza A (H1N1)pdm09 vaccine, 23-valent polysaccharide pneumococcal vaccine, and any of the pneumococcal conjugate vaccines, was obtained from medical records or vaccination cards. Cases were considered vaccinated if they had received a dose of the vaccine at least 14 days before symptom onset. Controls were considered vaccinated if they had received the dose at least 14 days before symptom onset in the matched case.
Statistical Analysis
We estimated the effectiveness of vaccination in preventing 3 main outcomes in patients with laboratory-confirmed influenza. Outpatient controls were considered the reference group and were compared with (1) outpatient cases, to estimate vaccination effectiveness in preventing medically attended influenza; (2) inpatient cases, to estimate effectiveness against influenza-related hospitalizations; and (3) severe inpatient cases, to estimate vaccine effectiveness in preventing influenza-related admissions to ICUs and deaths. In the sensitivity analysis, objectives 2 and 3 were also evaluated by comparison with inpatient controls. Additionally, inpatient cases were compared with outpatient cases, and severe inpatient cases were compared with nonsevere inpatient cases to assess vaccine effectiveness in preventing complications and disease progression in patients with influenza ( Figure 1 ).
Matched odds ratios (ORs) for vaccination, with their 95% confidence intervals (CIs), were calculated using conditional logistic regression models adjusted for potential confounding. Analyses including inpatient cases were also adjusted for pneumococcal vaccination. Matched groups lacking the outpatient case or control were excluded from the corresponding analyses.
Severe inpatient cases and nonsevere inpatient cases with confirmed influenza, which were not matched groups in the study design, were compared using unconditional logistic regression adjusted for the covariates mentioned, by age group (<5, 5-14, 15-44, 45-64, and ≥65 years) and by hospital ( Figure 1) .
To rule out possible confounding due to the type of influenza virus, the analyses were repeated for patients with influenza A (H1N1)pdm09 and their respective controls. We also performed separate analyses in people aged ≥65 years versus the remaining patients.
Bivariate comparisons were made using the χ 2 test or Student t test. Vaccine effectiveness was calculated as (1 -OR) × 100.
RESULTS
A total of 857 inpatients with confirmed influenza were considered for the study. Seventeen patients were excluded because influenza was acquired after hospital admission, 148 because they did not give consent to participate, and 1 because he or she had received antiviral treatment before admission. Therefore, 691 inpatients with confirmed influenza ("inpatient cases") were finally matched with 625 outpatients ("outpatient cases") with confirmed influenza, 671 outpatient controls, and 1326 inpatient controls. Of inpatient cases, 93% (n = 646) were due to influenza A(H1N1) pdm09 and the remainder to influenza B (n = 45), whereas all outpatient cases were caused by influenza A(H1N1)pdm09. Despite matching, outpatient cases were slightly younger than outpatient controls and inpatient cases. Pregnancy, pneumonia in the previous 2 years, and lack of influenza vaccination were more frequent among inpatient and outpatient cases. Current smoking was more frequent among inpatients cases and controls. Bed confinement 7 days before admission or medical visit, corticoid treatment, unplanned hospitalization in the previous 12 months, major chronic conditions, and pandemic influenza vaccination in the 2009-2010 season were more frequent in inpatient cases (Table 1 and Supplementary Table 1 ).
In the comparison of outpatient cases and outpatient controls using conditional logistic regression adjusted for the covariates mentioned, estimated vaccine effectiveness was 75% (adjusted OR [AOR], 0.25; 95% CI, .16-.39) in preventing outpatient cases with confirmed influenza. Comparison of inpatient cases with outpatient controls showed a vaccine effectiveness of 60% (AOR, 0.40; 95% CI, .25-.63) in preventing influenza-associated hospitalizations (Figure 2 ). However, vaccination had no appreciable effectiveness in preventing hospital admission of influenza cases when inpatient cases were compared with outpatient cases (AOR, 1.53, 95% CI, .86-2.72). The adjusted comparison between severe inpatient cases and outpatient controls showed that vaccination effectiveness increased to 89% (AOR, 0.11; 95% CI, .04-.37; Table 2 ).
In the sensitivity analysis using inpatient controls as the comparison group, the estimated vaccine effectiveness was 57% (AOR, 0.43; 95% CI, .29-.62) in preventing influenza-associated hospitalizations and 72% (AOR, 0.28; 95% CI, .12-.62) in preventing severe inpatient cases of influenza (Supplementary Table 2 ).
Repetition of the analyses including only cases of influenza A(H1N1)pdm09 showed similar results. The inclusion of the monovalent vaccination against influenza A(H1N1)pdm09 in the 2009-2010 season showed no effectiveness in preventing outpatient cases of influenza A(H1N1)pdm09 (AOR, 1.49; 95% CI, .76-2.92) and hardly modified the estimates of seasonal influenza vaccination effectiveness (Supplementary Table 3 ). Compared with subjects aged <65, those aged ≥65 had lower point estimates of influenza vaccine effectiveness in preventing inpatient cases and higher estimates in preventing severe cases, although none of these differences were statistically significant ( Of inpatient cases, 25.6% (177/691) were admitted to the ICU or died. Compared to nonsevere inpatient cases, severe inpatient cases were more often male, aged 45-64 years, and smokers; had a previous diagnosis of cardiovascular disease or diabetes mellitus; and less frequently had a diagnosis of pneumonia in the 2 previous years. There were no statistically significant differences in other characteristics (Table 3) . In inpatient cases, those vaccinated against influenza were less likely to be severe cases (AOR, 0.42; 95% CI, .22-.80), and this protective effect was even more pronounced in inpatient cases aged ≥65 years (AOR, 0.15; 95% CI, .03-.71), although the interaction between vaccine status and age group (<65 and ≥65 years) was not statistically significant (P = .513). After excluding patients who died from the analysis, there continued to be a lower, although nonsignificant, probability of vaccinated inpatient cases being severe cases (AOR, 0.51; 95% CI, .26-1.02). Repetition of the analysis including only cases of influenza A(H1N1)pdm09 showed similar results (Table 4 and Supplementary Table 5 ).
The mean time between the onset of influenza symptoms and the primary healthcare visit did not differ between vaccinated (2.5 ± 2.6 days) and unvaccinated (2.2 ± 2.0 days, P = .563) patients. In inpatient cases, there was no difference in the time between the onset of symptoms and hospital admission in vaccinated (5.1 ± 4.5 days) and unvaccinated (5.0 ± 4.2 days, P = .889) patients.
DISCUSSION
The results of this study show that the 2010-2011 influenza vaccine had a moderate to high effect in preventing outpatient cases and hospitalizations due to laboratory-confirmed influenza in Spain, and a high preventive effect against severe cases. Influenza vaccination was not associated with differences in the probability of hospitalization in influenza cases, but was associated with lesser severity in inpatients, especially in older patients.
The effectiveness in preventing outpatient cases was slightly higher than that reported by other authors in Europe and the United States in the same season using the test-negative casecontrol design [5, 6, 23] . Likewise, the effectiveness in preventing hospitalization found is in the range reported in other studies conducted in Spain using different designs [16, 17] . Both effects were consistent with the virus-vaccine match in this season in Spain [27] .
Vaccination was substantially effective in preventing severe cases: this was evident in comparisons with outpatient controls, inpatient controls, and nonsevere inpatient cases. This suggests that influenza vaccination was a factor for a good prognosis, reducing the incidence of complications and progression to more severe clinical forms in people in whom it did not prevent influenza infection. Vaccination generates an immune response and the production of antibodies but does not always prevent infection, but even in these cases it can reduce the viremia and the length of the illness, resulting in a better prognosis.
These findings could have alternative explanations. Vaccinated persons may attend hospital earlier, anticipating complications and avoiding evolution to severe forms: however, the time between the onset of symptoms and hospitalization was similar in vaccinated and unvaccinated patients. Likewise, we cannot totally discount the "healthy vaccinee effect" whereby frail patients may be less likely to be vaccinated and more likely to evolve to greater severity or death [26] ; however, severe and nonsevere inpatient cases were similar in many characteristics and the analyses were adjusted for factors related to frailty, such as pneumonia in the previous 2 years, bed confinement, and previous hospitalization. This effect remained in the analysis stratified by age, and was even more pronounced in older adults. The effect found was of sufficient magnitude that the possibility of it being due to factors unrecognized in the design and analysis is low. Vaccine effectiveness was assessed in severe cases of influenza confirmed by RT-PCR, in contrast to other studies that evaluated less specific outcomes [25, 28] .
These findings suggest that influenza vaccination may have additional benefits not detected by most studies evaluating vaccine effectiveness in confirmed cases. The prevention of severe cases of influenza, even though the numbers are lower, may have greater benefits in terms of health and health costs than the prevention of outpatient cases and nonsevere inpatient cases. It may also explain, at least partly, the substantial effectiveness of the vaccine in preventing deaths [25] . These findings reinforce the recommendation of annual influenza vaccination in people with risk factors and seniors.
Some studies have suggested that the pandemic influenza vaccine administered in the 2009-2010 season could have a residual protective effect in the 2010-2011 season [6, 10] , but we found no evidence for this, similar to other studies [11, 18] . Streptococcus pneumoniae can cause added complications in inpatient cases of influenza [29, 30] and pneumococcal vaccination could prevent hospitalizations regardless of influenza vaccination: for this reason, all analyses of inpatient cases were adjusted for a history of pneumococcal vaccination.
Most recent studies of influenza vaccine effectiveness compare laboratory-confirmed cases with negative controls [4] [5] [6] [7] [8] [9] [10] [11] , but the comparison between estimates against different outcomes cannot be usually made using this design. Using a conventional matched case-control design and analyzing subjects with comparable characteristics due to the matching used and adjustment for potential confounders, we studied the effect of influenza vaccination on 3 types of outcomes representing different levels of influenza severity. (46) 126 (24) 1.90 (1.09-3.30) .024 1.40 (.62-3.19) .419
This study had some possible limitations. The interviewers knew whether interviewees were cases or controls, and this could have influenced information gathering. However, the same protocol was followed in cases and controls, almost all of the data evaluated in this study were obtained by review of medical records, and information on the vaccination history was collected from medical records, vaccination cards, or registers; therefore, there is unlikely to be any relevant information bias. Despite the matching, selection bias due to the recruitment criteria for each group cannot be totally excluded; however, the consistent results of sensitivity analyses in a different control group (inpatient controls) suggest that this possible bias does not affect the main conclusions. If, during a comparison, a case had no matched control, it was excluded. This might have caused some differences in the characteristics of the population included in the different analyses. However, the number of incomplete matching groups was very small, and therefore it is unlikely this factor affected the results. The repetition of the analysis including only fully matched groups showed similar results to the main analysis. The study was conducted in a season in which the predominant influenza virus circulating was A(H1N1)pdm09, whose pattern of involvement might differ somewhat from other influenza viruses, and it would be interesting to compare our finding with those from other seasons. Finally, cases and controls were included in the study when they sought medical treatment, and this would have helped to make them more alike in the use of health services; however, the care-seeking patterns may have had some influence in the comparisons between inpatient and outpatient cases. The similarity between the estimates obtained in our study and in studies using other designs in the same season [5, 6, 16, 17, 23] would rule out the existence of important unmeasured confounders affecting the results.
In conclusion, this multicenter study, carried out in Spain in the 2010-2011 season, found that the influenza vaccine was moderately to highly effective in preventing outpatient and inpatient cases of laboratory-confirmed influenza. Moreover, in influenza patients, vaccination seems to improve the prognosis, avoiding evolution to greater severity. The combined effect of these 2 mechanisms was to prevent serious cases and deaths from influenza. This suggests that vaccination effectiveness may be greater in preventing severe cases than in preventing mild cases, and that the benefits of vaccination may be greater than suggested by most studies of effectiveness against confirmed cases. Our results reinforce the recommendation of annual influenza vaccination in high-risk populations.
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